FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313502951> ?p ?o ?g. }

• W4313502951 endingPage "8" @default.
• W4313502951 startingPage "8" @default.
• W4313502951 abstract "Objectives: This is a longitudinal prospective study which was designed to assess the trend of anti-SARS-CoV-2 antibodies targeting the Spike (anti-S) and Nucleocapside protein (anti-N) viral antigens over a 9-month period after the administration of an anti-SARS-CoV-2 vaccine in a big COVID-19 hospital located in Northern Italy. Participants: 7411 vaccinated workers were included in a linear mixed-effect model analysis performed to model the anti-S decay over the 9 months following the vaccination, during serological screening performed approximately 2, 4, and 9 months following the first jab administration. Serological tests performed in the 9 months preceding vaccine administration were retrospectively analysed to identify the burden of infections occurring before vaccination. Results: The serological assays were used for monitoring the antibody titres during the observational period. Vaccination significantly reduced the rate of infection and elicited a specific humoral response, which lasted during the whole observational period (9 months). A decay was observed in all considered subgroups. At 35 weeks, workers with no history of pre-vaccine infection showed a significantly lower anti-S titre (−2522 U/mL on average (−2589.7 to −2445.7)); younger workers showed significantly higher anti-S titres (140.2 U/mL on average (82.4 to 201.3)). Only seven immunocompromised workers did not show significant levels of anti-S antibodies; three of them, all females, showed a specific T-cell response. Conclusions: Comparing the 9-month periods before and after the first vaccine dose, a significant reduction in infection rate was observed (1708 cases vs. 156). Pre-vaccine infection, especially if contracted during the first pandemic wave, greatly enhanced the response to vaccination, which was significantly affected also by age both in extent and duration (inversely related). A gender effect on the T-cell immune response was observed in a small group of workers who did not produce antibodies after vaccine administration." @default.
• W4313502951 created "2023-01-06" @default.
• W4313502951 creator A5000824630 @default.
• W4313502951 creator A5005804929 @default.
• W4313502951 creator A5009391378 @default.
• W4313502951 creator A5032003577 @default.
• W4313502951 creator A5038812874 @default.
• W4313502951 creator A5041597868 @default.
• W4313502951 creator A5047949241 @default.
• W4313502951 creator A5052369911 @default.
• W4313502951 creator A5054677830 @default.
• W4313502951 creator A5057165095 @default.
• W4313502951 creator A5082772241 @default.
• W4313502951 creator A5089717604 @default.
• W4313502951 creator A5089739736 @default.
• W4313502951 date "2022-12-20" @default.
• W4313502951 modified "2023-09-30" @default.
• W4313502951 title "Immune Responses to SARS-CoV-2 Infection and Vaccine in a Big Italian COVID-19 Hospital: An 18-Month Follow-Up" @default.
• W4313502951 cites W2045019335 @default.
• W4313502951 cites W2126339385 @default.
• W4313502951 cites W2129939868 @default.
• W4313502951 cites W2518536270 @default.
• W4313502951 cites W2609522512 @default.
• W4313502951 cites W3046765292 @default.
• W4313502951 cites W3091555782 @default.
• W4313502951 cites W3110641745 @default.
• W4313502951 cites W3122043911 @default.
• W4313502951 cites W3130424776 @default.
• W4313502951 cites W3132798068 @default.
• W4313502951 cites W3133511640 @default.
• W4313502951 cites W3138326401 @default.
• W4313502951 cites W3152551199 @default.
• W4313502951 cites W3153039449 @default.
• W4313502951 cites W3163939566 @default.
• W4313502951 cites W3168075395 @default.
• W4313502951 cites W3197418831 @default.
• W4313502951 cites W3197540476 @default.
• W4313502951 cites W4200118071 @default.
• W4313502951 cites W4210792408 @default.
• W4313502951 cites W4225505755 @default.
• W4313502951 cites W4226046743 @default.
• W4313502951 cites W4226376477 @default.
• W4313502951 doi "https://doi.org/10.3390/vaccines11010008" @default.
• W4313502951 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36679853" @default.
• W4313502951 hasPublicationYear "2022" @default.
• W4313502951 type Work @default.
• W4313502951 citedByCount "3" @default.
• W4313502951 countsByYear W43135029512023 @default.
• W4313502951 crossrefType "journal-article" @default.
• W4313502951 hasAuthorship W4313502951A5000824630 @default.
• W4313502951 hasAuthorship W4313502951A5005804929 @default.
• W4313502951 hasAuthorship W4313502951A5009391378 @default.
• W4313502951 hasAuthorship W4313502951A5032003577 @default.
• W4313502951 hasAuthorship W4313502951A5038812874 @default.
• W4313502951 hasAuthorship W4313502951A5041597868 @default.
• W4313502951 hasAuthorship W4313502951A5047949241 @default.
• W4313502951 hasAuthorship W4313502951A5052369911 @default.
• W4313502951 hasAuthorship W4313502951A5054677830 @default.
• W4313502951 hasAuthorship W4313502951A5057165095 @default.
• W4313502951 hasAuthorship W4313502951A5082772241 @default.
• W4313502951 hasAuthorship W4313502951A5089717604 @default.
• W4313502951 hasAuthorship W4313502951A5089739736 @default.
• W4313502951 hasBestOaLocation W43135029511 @default.
• W4313502951 hasConcept C126322002 @default.
• W4313502951 hasConcept C159047783 @default.
• W4313502951 hasConcept C159654299 @default.
• W4313502951 hasConcept C203014093 @default.
• W4313502951 hasConcept C22070199 @default.
• W4313502951 hasConcept C22889606 @default.
• W4313502951 hasConcept C23131810 @default.
• W4313502951 hasConcept C2779134260 @default.
• W4313502951 hasConcept C3007834351 @default.
• W4313502951 hasConcept C3008058167 @default.
• W4313502951 hasConcept C32611913 @default.
• W4313502951 hasConcept C45189115 @default.
• W4313502951 hasConcept C524204448 @default.
• W4313502951 hasConcept C71924100 @default.
• W4313502951 hasConcept C8891405 @default.
• W4313502951 hasConceptScore W4313502951C126322002 @default.
• W4313502951 hasConceptScore W4313502951C159047783 @default.
• W4313502951 hasConceptScore W4313502951C159654299 @default.
• W4313502951 hasConceptScore W4313502951C203014093 @default.
• W4313502951 hasConceptScore W4313502951C22070199 @default.
• W4313502951 hasConceptScore W4313502951C22889606 @default.
• W4313502951 hasConceptScore W4313502951C23131810 @default.
• W4313502951 hasConceptScore W4313502951C2779134260 @default.
• W4313502951 hasConceptScore W4313502951C3007834351 @default.
• W4313502951 hasConceptScore W4313502951C3008058167 @default.
• W4313502951 hasConceptScore W4313502951C32611913 @default.
• W4313502951 hasConceptScore W4313502951C45189115 @default.
• W4313502951 hasConceptScore W4313502951C524204448 @default.
• W4313502951 hasConceptScore W4313502951C71924100 @default.
• W4313502951 hasConceptScore W4313502951C8891405 @default.
• W4313502951 hasIssue "1" @default.
• W4313502951 hasLocation W43135029511 @default.
• W4313502951 hasLocation W43135029512 @default.
• W4313502951 hasLocation W43135029513 @default.
• W4313502951 hasLocation W43135029514 @default.

• next